Editorial Board

52 Editors in 11 Countries/Regions

USA (21)
China (9)
Italy (8)
Netherlands (5)
United Kingdom (2)
Australia (2)
Israel (1)
Germany (1)
Belgium (1)
France (1)
Singapore (1)

Editor-in-Chief

Godefridus J. Peters

gj.peters@amsterdamumc.nl

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.

Research Interests: cancer biomarkers, apoptosis, lung diseases, cell culture, gene expression, pharmacokinetics, pharmacodynamics and pharmacogenetics of anticancer drugs, gastrointestinal cancers, translational research, animal models, drug metabolism and transport, influx and efflux proteins.

Contributions:

SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells

Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Cancer drug resistance: a new perspective

Special Issue:

Papers from the Meeting of the European Organization of Research and Treatment of Cancer (EORTC) - Pharmacology and Molecular Mechanisms (PAMM) Group

Co-Editor-in-Chief

Yehuda G. Assaraf

Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel.

Research Interests: molecular mechanisms of anticancer drug resistance, drug discovery, physiology.

Contributions:

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells

Associate Editors

Liwu Fu

State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Research Interests: ABC transporter, cancer therapy, chemotherapy resistance, multidrug resistance, immune checkpoint blockade, leukemia.

Contributions:

Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response

Special Issue:

Tumor Microenvironment and Drug Resistance

Microvesicle and Cancer Drug Resistance

Paola Perego

Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Research Interests: molecular biology, p53, DNA damage, apoptosis, cytotoxicity, pharmacology, cancer cell line.

Contributions:

Tackling cisplatin resistance in ovarian cancer: what can we do?

Special Issue:

Tackling Cisplatin Resistance in Ovarian Cancer

Drug Resistance in Melanoma: Mechanistic Insights and Overcoming Strategies

Chiara Riganti

Department of Oncology, University of Torino, Torino, Italy.

Research Interests: chemo-immunoresistant tumor models, lung cancer, prostate cancer, breast cancer, malignant pleural mesothelioma, glioblastoma multiforme, multiple myeloma.

Contributions:

Overcoming drug resistance in glioblastoma: new options in sight?

Special Issue:

New challenges in overcoming chemoresistance in Glioblastoma

Tackling the Challenge of Drug Resistance in Lung Cancer

Hailin Tang

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Research Interests: cancer, metastasis, metabolism, animal model, non-coding RNA.

Special Issue:

Role of Non-Coding RNA in Cancer Drug Resistance

Editorial Board Members

Aamir Ahmad

Dermatology Institute and Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Research Interests: non-coding RNAs expression, signaling in cancer metastasis, circulating and tissue biomarkers.

Special Issue:

Epigenetic Basis of Cancer Drug Resistance

Suresh V. Ambudkar

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Research Interests: ATP-binding cassette (ABC) drug transporters, drug resistance, membrane biochemistry, chemoresistance, transport proteins.

Contributions:

The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducers

New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection

Speical Collection:

New Mechanisms of Multidrug Resistance

Maria R. Baer

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Research Interests: acute myeloid leukemia, FLT3 internal tandem duplication, signaling pathways, kinase inhibitors, drug resistance.

Stergios Boussios

Faculty of Life Sciences and Medicine, King's College London, London, UK.

Research Interests: cancer treatment, cancer in pregnancy, cancer diagnostics, cancer biology, cancer biomarkers, gynaecological cancers, urological cancers, colorectal cancer, autoimmunity.

Claudio Cerchione

Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Research Interests: myelodysplastic syndromes, hematological malignancies, lymphoma, multiple myeloma, hematologic diseases, clinical hematology, blood disorders, acute myeloid leukemia, chemotherapy, leukemia, acute lymphoblastic leukemia.

Special Issue:

Research Progress on Drug Resistance in Acute Myeloid Leukemia

Novel Agents in Multiple Myeloma: Exploring Drug Resistance and New Opportunities

Wei Chen

Department of Physics, The University of Texas at Arlington, Arlington, TX, USA.

Research Interests: nanomedicine, cancer nanotechnology, drug delivery, targeting, hypoxia, cancer resistance, radiotherapy, photodynamic therapy, photothermal therapy, chemodynamic therapy.

Contributions:

Some synergetic therapy strategies for overcoming hypoxia for photodynamic therapy of cancer

Tuning Ag+ and Mn2+ doping in ZnS:Ag,Mn embedded polymers for flexible white light emitting films

Special Issue:

The Role of Nanotechnology in Cancer: Current Status and Challenges

Zhesheng Chen

Department of Pharmaceutical Sciences, St. John’s University, Queens, NY, USA.

Research Interests: ABC transporters, multidrug resistance, cancer pharmacology.

William C. Cho

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.

Research Interests: cancer biomarkers, drug repurposing, non-coding RNA, proteomics.

Contributions:

Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance

Special Issue:

The Emerging Role of Extracellular Vesicles in Cancer

Jacqueline Cloos

Department of Hematology, VU University Medical Center, Amsterdam, Netherlands.

Research Interests: proteasome inhibitors, minimal residual disease, clonal evolution, splicing, cellular drug addiction, hematology, drug combination studies.

Contributions:

Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells

Paul Dent

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.

Research Interests: cancer therapeutics, rational combination of drugs, molecular mechanisms, drug combinations synergize, breast, brain, liver and pancreatic cancers.

Contributions:

Kinase inhibitors: look beyond the label on the bottle

Changming Dong

School of Chemistry & Chemical Engineering, Shanghai Jiao Tong University, Shanghai, China.

Research Interests: biodegradable polymer nanomedicine, cancer combination therapy, drug delivery systems, multidrug resistance.

Thomas Efferth

Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.

Research Interests: natural product chemistry, medicinal and pharmaceutical chemistry, virtual drug screening, transcriptomics, network pharmacology, biochemistry, drug development, apoptosis, cancer biology.

Contributions:

Drug targets and resistance mechanisms in multiple myeloma

Special Issue:

Drug Resistance in Metastatic Castration-Resistant Prostate Cancer

New Insights and Emerging Targets in Cancer Drug Resistance

Marco Falasca

Curtin Health Innovation Research Institute, Curtin University, Perth, Australia.

Research Interests: pancreatic cancer, exosomes, lipid metabolism, membrane transporters, signal transduction, cancer invasion and metastasis, phosphoinositide signalling, cannabinoids.

Special Issue:

Treatment of Pancreatic Cancer

David Gewirtz

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.

Research Interests: autophagy, senescence, cancer chemotherapy, chemosensitization, radiosensitization, chemtoxicity.

Contributions:

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

Jean-Pierre Gillet

Laboratory of Molecular Cancer Biology, Faculty of Medicine, University of Namur, Namur, Belgium.

Research Interests: ATP-binding cassette transporters, cancer multidrug resistance mechanisms, pharmacogenomics, cancer biology, transcriptomics.

William Gmeiner

Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Research Interests: colorectal cancer, fluoropyrimidine, thymidylate synthase, DNA topoisomerase, aberrant signaling pathways in tumor cells.

Contributions:

Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs

Targeting DNA topoisomerases: past & future

Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations

Special Issue:

Targeting DNA Topoisomerases – Past and Future

Michael M Gottesman

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Research Interests: cancer therapy, drug resistance, nanotechnology, theranostics, biomarker.

Contributions:

New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection

The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducers

Speical Collection:

New Mechanisms of Multidrug Resistance

Dominique Heymann

Institut de Cancérologie de l'Ouest, Tumour Heterogeneity and Precison Medicine Laboratory, Saint-Herblain, France.

Research Interests: circulating tumour cells, pathogenesis of bone sarcoma, osteoclast differentiation, metastatic process.

Contributions:

Exosomal lncRNAs: the newest promising liquid biopsy

Drug resistance in glioblastoma: are persisters the key to therapy?

Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma

Zhiqing Huang

Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Duke University Medical Center, Durham, NC, USA.

Research Interests: ovarian cancer, cancer chemoresistance, tumor microenvironment, epigenetics and epigenomics.

Thomas E. Hutson

Hematology and Medical Oncology, UC Davis Health, Sacramento, CA, USA;
UMC Cancer Center, Lubbock, TX, USA; Texas Tech University Health Science Center, Lubbock, TX, USA.

Research Interests: renal cell carcinoma, bladder cancer, prostate cancer, testicular cancer, immunotherapy.

Gerrit Jansen

Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands.

Research Interests: rheumatology, cancer biology and immunology, imaging and biomarkers, inflammatory diseases, antifolates, proteasome inhibitors, (multi) drug resistance.

Contributions:

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Dexin Kong

School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin, China.

Research Interests: molecular targeted drug, natural products, cancer chemotherapy, traditional Chinese medicine in anti-tumor treatment.

Hang Fai Kwok

Faculty of Health Sciences, University of Macau, Macau, China.

Research Interests: novel therapeutic antibodies development, venom-based peptide & natural biomolecule prototype drugs development, cancer biomarkers & immunotherapy markers discovery for prognostic and therapeutic validation.

Special Issue:

Application of Biomarkers in Tumor Clonal Evolution and Cancer Drug Resistance

Saverio Marchi

Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.

Research Interests: cell signaling, cancer biology, cell death, molecular cell biology, mitochondria, calcium.

Enrico Mini

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Research Interests: leukemia, antimetabolites and metal-based drug resistance, gastrointestinal cancers, cancer pharmacogenomics, pharmacogenetics.

Contributions:

“Pharmacogenetics of Cancer” - Cancer Drug Resistance special issue

Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients

Special Issue:

Pharmacogenetics of cancer

Pharmacogenomics and Pharmacogenetics of Cancer

Gianpaolo Papaccio

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Research Interests: cancer stem cells, peritumoral tissue, mitochondrial transfer, organoids, adipose stem cells and cancer, hyaluronans and cancer.

Roger M. Phillips

Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK.

Research Interests: tumour hypoxia, cancer metabolism, hypoxia activated prodrugs, drug discovery (including phenotypic drug evaluation), drug delivery to the tumour microenvironment.

Raphael E. Pollock

Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

Research Interests: sarcoma, neoplasms, neurilemmoma, gastrointestinal stromal tumors, breast neoplasms, leiomyosarcoma, neoplasm metastasis, ewing, liposarcoma, myxoid, liposarcoma.

Paolo Ettore Porporato

Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Turin, Turin, Italy.

Research Interests: cancer metabolism, muscle atrophy, mitochondrial ROS, cachexia, iron.

Jiangjiang Qin

Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

Research Interests: gastric cancer, pancreatic cancer, new target discovery, molecular mechanism of new targets, innovative drugs.

Robert W. Robey

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Research Interests: cancer drug resistance, ATP-binding cassette transporters, ABCG2, histone deacetylase inhibitors, METTL7A.

Contributions:

The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducers

New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection

Speical Collection:

New Mechanisms of Multidrug Resistance

Ahmad R Safa

Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.

Research Interests: cancer drug resistance, cancer stem cells, apoptosis resistance, anti-apoptotic roteins, pro-apoptotic proteins.

Contributions:

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

John D. Schuetz

Department of Pharmacy and Pharmaceutical Science, St. Jude Children's Research Hospital, Memphis, TN, USA.

Research Interests: role of ABC transporters in response to chemotherapy, biological function of ABC transporters, regulation of ABC transporters.

Gautam Sethi

Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore.

Research Interests: cancer, cellular and molecular mechanisms, diagnostics and therapeutics, gastrointestinal cancer.

Special Issue:

Nanoarchitectures and Natural-based Products in Cancer Drug Resistance: Time to Converge Biology and Engineering

John Seymour

Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne, Victoria, Australia.

Research Interests: haematology, aggressive lymphoma, acute leukemia, myelodysplasia.

Contributions:

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

Rakesh Srivastava

Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health-New Orleans, New Orleans, LA, USA.

Research Interests: apoptosis, cell signaling and human diseases, molecular mechanisms, stem cells and human diseases, nutrition, diet and cancer.

Chunxia Su

Department of Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.

Research Interests: non-small cell lung cancer, lung cancer, tumor microenvironment, immunotherapy.

Contributions:

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Immunotherapy resistance of lung cancer

Emerging insights to lung cancer drug resistance

Special Issue:

Lung Cancer Drug Resistance

Dean G Tang

Professor & Chairman, Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Research Interests: cancer stem cells, prostate cancer, stem cells, cancer cell heterogeneity, lineage plasticity, therapy resistance, cancer vaccine.

Kenneth Kin Wah To

School of Pharmacy, the Chinese University of Hong Kong, Hong Kong, China.

Research Interests: multidrug resistance in cancer chemotherapy, drug repurposing, cancer epigenetics.

Contributions:

Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance

Robert C.A.M. van Waardenburg

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA.

Research Interests: DNA repair proteins, cellular response to chemotherapy, protein-protein interactions, post-translational modification by ubiquitin and SUMO, sulfotransferases.

Contributions:

Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts

Targeting DNA repair pathways to overcome cancer drug resistance

Sphingolipid metabolism and drug resistance in ovarian cancer

Targeting DNA topoisomerases: past & future

Special Issue:

Targeting DNA Topoisomerases – Past and Future

Advances in DNA Damage & Repair and Cancer Drug Resistance

Erik A. C. Wiemer

Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.

Research Interests: cancer biology, biomarkers, non-coding RNAs, soft tissue sarcomas, lung cancer, ovarian cancer.

Dong-Hua Yang

New York College of Traditional Chinese Medicine, Mineola, NY, USA.

Research Interests: biomarker, pharmacology, multi-drug resistance, cancer biology, Chinese medicine, immunohistochemistry.

Xiaohe Yang

Biological and Biomedical Sciences, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, USA.

Research Interests: Cancer stem cells, apoptosis, receptor tyrosine kinase, cell cycle, therapeutic resistance, carcinogenesis, DNA damage, cell signaling.

All members of the Editorial Board have identified their affiliated institutions or organizations, along with the corresponding country or geographic region. OAE Publishing Inc. remains neutral with regard to any jurisdictional claims.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/